Clinical · Molecular biology · Bioinfo & AI
Integrative multi-omics and experimental validation reveal UBE2C as a central hub gene and prognostic biomarker in hepatocellular carcinoma
Summary
This multi-omics and experimental study identifies Ubiquitin-conjugating enzyme E2 C (UBE2C) as a central hub gene and a key prognostic biomarker in hepatocellular carcinoma (HCC). UBE2C is significantly upregulated in HCC, predominantly in hepatocytes, and its knockdown suppresses tumor proliferation and growth. The study reveals that UBE2C-high regions are associated with an immunosuppressive microenvironment, characterized by TGFB1 enrichment and cytotoxic T-cell exclusion. A nomogram integrating UBE2C expression, T stage, and tumor stage was developed to predict patient survival and stratify immunotherapy response.
Critical appraisal
Clinical. This research positions UBE2C as a prognostic and predictive biomarker for immunotherapy response in hepatocellular carcinoma. The nomogram, based on UBE2C, T stage, and tumor stage, provides a robust tool for predicting patient survival, which could guide clinical decisions and patient stratification for immunotherapy trials. Validation of this nomogram in prospective cohorts could justify a change in clinical practice, allowing for better selection of patients for existing or future treatments. Clinical impact could be seen in the medium term (3-5 years) if validation studies are conducted promptly.
Molecular biology. The study discovered UBE2C as a significantly upregulated hub gene in HCC, playing a crucial role in tumor progression by promoting proliferation and inhibiting apoptosis. Single-cell transcriptomics revealed its predominant expression in hepatocytes and dynamic upregulation. Spatial transcriptomics highlighted the link between UBE2C-high regions and an immunosuppressive microenvironment, involving TGFB1 enrichment and impaired CXCL9-CXCR3 signaling, leading to cytotoxic T-cell exclusion. These findings, validated by qPCR and immunoblotting in HCC tissues and cell lines, identify UBE2C as a potential target for novel therapies aimed at modulating the tumor immune microenvironment.
Bioinfo & AI. The integrative bioinformatics approach combined co-expression networks and protein-protein interaction analyses from public databases (TCGA, GEO, CPTAC) to identify hub genes. Analysis of single-cell and spatial transcriptomics data allowed for characterization of UBE2C expression and its impact on the tumor microenvironment with spatial and cellular resolution. The construction of a prognostic nomogram via multivariate Cox regression demonstrates a direct clinical application of bioinformatics data for survival prediction. These reproducible methods, leveraging public data, could be integrated into clinical workflows for patient stratification.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology